User profiles for Pierre Fumoleau
Pierre FumoleauInstitut Curie Verified email at curie.fr Cited by 32062 |
[PDF][PDF] Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results
…, JP Ayoub, G Cervantes, P Fumoleau… - Journal of clinical …, 2002 - researchgate.net
Purpose: Docetaxel and capecitabine, a tumor-acti-vated oral fluoropyrimidine, show high
single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies. …
single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies. …
Identification of molecular apocrine breast tumours by microarray analysis
…, V Becette, M Tubiana-Hulin, P Fumoleau… - Breast Cancer …, 2005 - Springer
S2 cancer in the general population remains unclear. Furthermore, the methodology of ATM
mutation detection is still laborious and costly. Because the ATM protein kinase …
mutation detection is still laborious and costly. Because the ATM protein kinase …
[PDF][PDF] Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial
H Roché, P Fumoleau, M Spielmann… - Journal of Clinical …, 2006 - researchgate.net
Purpose The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide
(FEC) with a sequential regimen of three cycles of FEC followed by three cycles of …
(FEC) with a sequential regimen of three cycles of FEC followed by three cycles of …
[HTML][HTML] Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed …
…, VA McNally, GA Ross, P Fumoleau… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Pertuzumab, a human epidermal growth factor receptor 2 (HER2)–targeted monoclonal
antibody, potently inhibits HER2 dimerization and HER-mediated signaling pathways. …
antibody, potently inhibits HER2 dimerization and HER-mediated signaling pathways. …
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
…, T Bachelot, A Lortholary, M Espié, P Fumoleau… - The lancet …, 2013 - thelancet.com
Background Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment
for patients with HER2-positive early-stage breast cancer. However, the optimum duration …
for patients with HER2-positive early-stage breast cancer. However, the optimum duration …
[PDF][PDF] Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
…, AD Seidman, B Chevallier, P Fumoleau… - Journal of clinical …, 1998 - Citeseer
Conclusion: First-course docetaxel PK is a predictor of first-course hematologic toxicity, but
also of fluid retention, which is cumulative in nature. Patients with elevated hepatic enzymes …
also of fluid retention, which is cumulative in nature. Patients with elevated hepatic enzymes …
Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T …
…, B Coudert, F Martin, B Chauffert, P Fumoleau… - Clinical cancer …, 2008 - AACR
Purpose: T-cell infiltration is associated with good tumor prognosis in many cancers. To assess
the capacity of neoadjuvant chemotherapy to affect T-cell infiltration in breast cancer, we …
the capacity of neoadjuvant chemotherapy to affect T-cell infiltration in breast cancer, we …
[HTML][HTML] Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally …
…, RC Guimaraes, P Fumoleau… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
Purpose Recent data showed improvement in progression-free survival (PFS) when adding
everolimus to exemestane in patients with advanced breast cancer experiencing recurrence/…
everolimus to exemestane in patients with advanced breast cancer experiencing recurrence/…
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer
…, M Fornier, P Conté, P Fumoleau… - Journal of Clinical …, 2007 - ascopubs.org
Purpose Ixabepilone (BMS-247550) is an epothilone analog that optimizes the properties of
naturally occurring epothilone B. Natural epothilones and their analogs promote tumor cell …
naturally occurring epothilone B. Natural epothilones and their analogs promote tumor cell …
[PDF][PDF] Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced …
J Cortés, P Fumoleau, GV Bianchi, TM Petrella… - J Clin Oncol, 2012 - academia.edu
Purpose The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR)
of 50% in patients with human epidermal growth factor receptor 2 (HER2)–positive …
of 50% in patients with human epidermal growth factor receptor 2 (HER2)–positive …